• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

作者信息

Mosquera-Orgueira Adrián, Arellano-Rodrigo Eduardo, Garrote Marta, Martín Iván, Pérez-Encinas Manuel, Gómez-Casares María-Teresa, Hernández-Sánchez Alberto, Ferrer-Marín Francisca, Mora Elvira, Velez Patricia, Ayala Rosa, Angona Anna, Heras Natalia de Las, Magro Elena, Pérez-Míguez Carlos, Crucitti Davide, Mata-Vázquez María-Isabel, Fox María-Laura, González de Villambrosía Sonia, Ramírez María-José, García Ana, García-Gutiérrez Valentín, Cáceres Amparo, Durán María-Antonia, Senín María-Alicia, Raya José-María, González José A, Cuevas Beatriz, Xicoy Blanca, Nangalia Jyoti, Hernández-Rivas Jesús M, Bellosillo Beatriz, Álvarez-Larrán Alberto, Hernández-Boluda Juan C

机构信息

Santiago de Compostela Hospital Clínico Universitario Valencia Spain.

Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain.

出版信息

Hemasphere. 2024 Mar 20;8(3):e60. doi: 10.1002/hem3.60. eCollection 2024 Mar.

DOI:10.1002/hem3.60
PMID:38510992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10951878/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0c/10951878/b5d7b8e6b656/HEM3-8-e60-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0c/10951878/57280b2986b3/HEM3-8-e60-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0c/10951878/b5d7b8e6b656/HEM3-8-e60-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0c/10951878/57280b2986b3/HEM3-8-e60-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0c/10951878/b5d7b8e6b656/HEM3-8-e60-g002.jpg

相似文献

1
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.整合AIPSS-MF与分子预测指标：骨髓纤维化预后模型的比较分析
Hemasphere. 2024 Mar 20;8(3):e60. doi: 10.1002/hem3.60. eCollection 2024 Mar.
2
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.AIPSS-MF 机器学习预后评分在接受鲁索利替尼治疗的骨髓纤维化患者队列中的验证。
Cancer Rep (Hoboken). 2023 Oct;6(10):e1881. doi: 10.1002/cnr2.1881. Epub 2023 Aug 8.
3
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.机器学习改善骨髓纤维化的风险分层：西班牙骨髓纤维化登记处的分析
Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. eCollection 2023 Jan.
4
[Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化中国患者的预后因素分析
Zhonghua Xue Ye Xue Za Zhi. 2016 Oct 14;37(10):876-880. doi: 10.3760/cma.j.issn.0253-2727.2016.10.012.
5
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.骨髓纤维化中的与疾病相关的血小板减少症由不同的遗传病因定义，并与独特的预后相关因素相关。
Cancer. 2022 Oct 1;128(19):3495-3501. doi: 10.1002/cncr.34414. Epub 2022 Aug 9.
6
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.原发性骨髓纤维化和真性红细胞增多症后/或原发性血小板增多症后骨髓纤维化患者接受芦可替尼治疗的临床表现、结局和预后模型的差异。一项大型多中心研究中 MYSEC-PM 的新视角。
Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.
7
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.原发性血小板增多症后和真性红细胞增多症后的患者与原发性骨髓纤维化患者有所不同。
Leuk Res. 2017 Aug;59:110-116. doi: 10.1016/j.leukres.2017.06.001. Epub 2017 Jun 2.
8
The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.欧洲骨髓纤维化分级共识有助于更好地预测原发性骨髓纤维化患者的预后。
Mod Pathol. 2012 Sep;25(9):1193-202. doi: 10.1038/modpathol.2012.87. Epub 2012 May 25.
9
The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.真性红细胞增多症后骨髓纤维化和原发性血小板增多症后骨髓纤维化与原发性骨髓纤维化的预后的逐步认识。
Clin Adv Hematol Oncol. 2019 May;17(5):299-307.
10
Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.中国骨髓纤维化患者的临床病理特征及预后指标
Hematology. 2016 Jan;21(1):10-8. doi: 10.1179/1607845415Y.0000000045. Epub 2015 Aug 20.

引用本文的文献

1
Prognostic and Predictive Models in Myelofibrosis.骨髓纤维化的预后和预测模型。
Curr Hematol Malig Rep. 2024 Oct;19(5):223-235. doi: 10.1007/s11899-024-00739-6. Epub 2024 Aug 24.

本文引用的文献

1
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.骨髓纤维化异基因造血干细胞移植的适应证和处理：EBMT/ELN 国际工作组的更新建议。
Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4.
2
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.AIPSS-MF 机器学习预后评分在接受鲁索利替尼治疗的骨髓纤维化患者队列中的验证。
Cancer Rep (Hoboken). 2023 Oct;6(10):e1881. doi: 10.1002/cnr2.1881. Epub 2023 Aug 8.
3
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation.
TP53 对接受造血干细胞移植的骨髓纤维化患者结局的影响。
Blood. 2023 Jun 8;141(23):2901-2911. doi: 10.1182/blood.2023019630.
4
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.机器学习改善骨髓纤维化的风险分层：西班牙骨髓纤维化登记处的分析
Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. eCollection 2023 Jan.
5
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.原发性和继发性骨髓纤维化的基因组分析重新定义了 ASXL1 突变的预后影响：FIM 研究。
Blood Adv. 2021 Mar 9;5(5):1442-1451. doi: 10.1182/bloodadvances.2020003444.
6
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.RAS 通路突变对骨髓纤维化患者预后的影响。
Leukemia. 2020 Mar;34(3):799-810. doi: 10.1038/s41375-019-0603-9. Epub 2019 Oct 18.
7
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.骨髓增殖性肿瘤的分类与个体化预后
N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.
8
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.GIPSS：原发性骨髓纤维化的基因启发预后评分系统。
Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.
9
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.费城染色体阴性经典骨髓增殖性肿瘤：欧洲白血病网的修订管理建议。
Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.
10
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.MIPSS70：原发性骨髓纤维化移植年龄患者的突变增强国际预后评分系统。
J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.